Do you want to read an article? Please log in or register.
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis
Leukemia
Related content
Lung, Respiratory and Thoracic Cancer
Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy
J Thorac Oncol
Wiesweg M, Alaffas A, Rasokat A, Saalfeld FC, Rost M, Assmann C, Herster F, Hilbrandt M, Griesinger F, Kron A, Roeper J, Glanemann F, Kropf-Sanchen C, Reck M, Kulhavy J, Stenzinger A, Wolf J, Sebastian M, Schuler M, Wermke M, Frost N, Kopp HG, Christopoulos P, Scheffler M
doi: 10.1016/j.jtho.2025.04.016
RECOMMENDED
Gynecologic Cancer
First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Cancer Treat Rev
Petrelli F, Riboldi V, Bruschieri L, Villa A, Cribiu' FM, Borgonovo K, Ghilardi M, Ghidini A, Seghezzi S, Stefani A, Trevisan F
doi: 10.1016/j.ctrv.2025.102921
Gastrointestinal Cancer
First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306
Adv Ther
Xu J, Kato K, Hubner R, Park SR, Kojima T, Ishihara R, Wyrwicz L, Van Cutsem E, Jimenez-Fonseca P, Wu H, Wang L, Yan S, Shi J, Kadva A, Yoon HH
doi: 10.1007/s12325-025-03115-9
Gynecologic Cancer
Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis
Eur J Cancer
Villacampa G, Eminowicz G, Navarro V, Carità L, García-Illescas D, Oaknin A, Pérez-Fidalgo JA
doi: 10.1016/j.ejca.2025.115329
Gastrointestinal Cancer
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305
Adv Ther
Moehler M, Oh DY, Kato K, Arkenau T, Tabernero J, Lee KW, Rha SY, Hirano H, Spigel D, Yamaguchi K, Wyrwicz L, Disel U, Pazo-Cid RA, Fornaro L, Xu Y, Sheng T, Yang S, Kadva A, Cruz-Correa M, Xu RH
doi: 10.1007/s12325-025-03133-7
Gastrointestinal Cancer
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306
Eur J Cancer
Holch JW, Ohnmacht AJ, Stintzing S, Heinrich K, Weiss L, Probst V, Stahler A, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Heintges T, Kahl C, Kullmann F, Link H, Höffkes HG, Moehler M, Modest DP, Menden MP, Heinemann V
doi: 10.1016/j.ejca.2025.115388
Genitourinary Cancer
Avelumab + axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase 3 JAVELIN Renal 101 trial
Ann Oncol
Choueiri TK, Penkov K, Uemura H, Campbell MT, Pal S, Kollmannsberger C, Lee JL, Venugopal B, van den Eertwegh AJM, Negrier S, Gurney H, Albiges L, Berger R, Haanen JBAG, Oyervides Juárez V, Rini BI, Larkin J, Nolè F, Schmidinger M, Atkins MB, Tomita Y, Ellers-Lenz B, Hoffman J, Sandner R, Wang J, di Pietro A, Motzer RJ
doi: 10.1016/j.annonc.2024.12.008
Lung, Respiratory and Thoracic Cancer
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)
Lung Cancer
Ou SH, Kilvert H, Candlish J, Lee B, Polli A, Thomaidou D, Le H
doi: 10.1016/j.lungcan.2024.107968
Gastrointestinal Cancer
First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial
JAMA Oncol
Bond MJG, Bolhuis K, Loosveld OJL, de Groot JWB, Droogendijk H, Helgason HH, Hendriks MP, Klaase JM, Kazemier G, Liem MSL, Rijken AM, Verhoef C, de Wilt JHW, de Jong KP, Gerhards MF, van Amerongen MJ, Engelbrecht MRW, van Lienden KP, Hermans JJ, Molenaar IQ, Grünhagen DJ, de Valk B, Haberkorn BCM, Kerver ED, Erdkamp F, van Alphen RJ, Mathijssen-van Stein D, Komurcu A, May AM, Swijnenburg RJ, Punt CJA, Dutch Colorectal Cancer Group
doi: 10.1001/jamaoncol.2024.5174